Tianjin TEDA Biomedical Engineering Full Year 2023 Earnings: CN¥0.008 loss per share (vs CN¥0.015 loss in FY 2022)
Tianjin TEDA Biomedical Engineering (HKG:8189) Full Year 2023 Results
Key Financial Results
- Revenue: CN¥398.0m (down 12% from FY 2022).
- Net loss: CN¥14.6m (loss narrowed by 48% from FY 2022).
- CN¥0.008 loss per share (improved from CN¥0.015 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Tianjin TEDA Biomedical Engineering shares are down 3.4% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 1 warning sign for Tianjin TEDA Biomedical Engineering you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Tianjin TEDA Biomedical Engineering might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:8189
Tianjin TEDA Biomedical Engineering
Engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People’s Republic of China.
Very low with worrying balance sheet.